ArticleNature communications2021
SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.International journal of biological sciences · 2022Pooled it
- Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review.International journal of immunopathology and pharmacologyPooled it
- Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.Journal of virology · 2025Review
- Reduced spike specific T-cell responses in COVID-19 vaccinated subjects undergoing SARS-CoV-2 breakthrough infection.Frontiers in immunology · 2025Article
- Adjuvanted subunit intranasal vaccine reduces SARS-CoV-2 onward transmission in hamsters.Frontiers in immunology · 2025Article
- COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.Vaccine: X · 2024Review
- Impacts of Vaccination and Severe Acute Respiratory Syndrome Coronavirus 2 Variants Alpha and Delta on Coronavirus Disease 2019 Transmission Dynamics in Four Metropolitan Areas of the United States.Bulletin of mathematical biology · 2024Article
- Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave.Scientific reports · 2023Article
- Comparison of self-reported symptoms in COVID-19 patients who had or had not previously received COVID-19 mRNA vaccination.Human vaccines & immunotherapeutics · 2023Article
- The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.Pathogens (Basel, Switzerland) · 2023Review
- SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection.Nature communications · 2023Article
- Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2.Frontiers in immunology · 2023Article
- At what frequency of vaccination do the vaccinated potentially pose an equal risk to the unvaccinated for transmission of SARS-CoV-2 inside restaurants in New York City?Wiener klinische Wochenschrift · 2022Article
- Emerging trends of research on mRNA vaccines: A co-citation analysis.Human vaccines & immunotherapeutics · 2022Article
- Article
- Article
- Article
- Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.mSphere · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
Funding
Abstract
Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects, with a 100-day cumulative incidence of 0.93%. Vaccine protection against acquisition of SARS-CoV-2 infection is 83% (95%CI: 58-93%) in the overall population and 93% (95%CI: 69-99%) in SARS-CoV-2-experienced subjects, when compared with a non-vaccinated control group from the same Institution, in which SARS-CoV-2 infection occurs in 20/346 subjects (100-day cumulative incidence: 5.78%). The infection is symptomatic in 16 (48%) vaccinated subjects vs 17 (85%) controls (p = 0.01). All analyzed patients, in whom the amount of viral RNA was sufficient for genome sequencing, results infected by the alpha variant. Antibody and T-cell responses are not reduced in subjects with breakthrough infection. Evidence of virus transmission, determined by contact tracing, is observed in two (6.1%) cases. This real-world data support the protective effect of BNT162b2 vaccine. A triple antigenic exposure, such as two-dose vaccine schedule in experienced subjects, may confer a higher protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.